×
About 2,432 results

ALLMedicine™ Beta-thalassemia Center

Research & Reviews  1,191 results

A Rare Case of von Willebrand Disease Presenting as Hemolacria and Literature Review.
https://doi.org/10.1097/MPH.0000000000002077
Journal of Pediatric Hematology/oncology; Nandakumal G, Ismail F et. al.

Feb 9th, 2021 - Hemolacria is a rare condition that causes a person to produce tears that are partially composed of blood. It can be a presenting feature of certain ocular and systemic conditions. Here, the authors describe an interesting case of a 12-year-old bo...

Beta-Thalassemia - GeneReviews® - NCBI Bookshelf
https://www.ncbi.nlm.nih.gov/books/n/gene/b-thal/

Feb 3rd, 2021 - Beta-thalassemia (β-thalassemia) is characterized by reduced synthesis of the hemoglobin subunit beta (hemoglobin beta chain) that results in microcytic hypochromic anemia, an abnormal peripheral blood smear with nucleated red blood cells, and red...

The effect of curcumin on serum copper, zinc, and zinc/copper ratio in patients with β-...
https://doi.org/10.1007/s00277-021-04397-z
Annals of Hematology; Saeidnia M, Nowrouzi-Sohrabi P et. al.

Jan 12th, 2021 - Thalassemia intermedia is a subgroup of β-thalassemia which originates from mutations in the beta-globin gene. Zinc and copper play important roles in the metabolism. Due to its significant therapeutic effects, curcumin has led many studies to foc...

Denosumab versus zoledronic acid for patients with beta-thalassemia major-induced osteo...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7748343
Medicine Yassin MA, Abdel Rahman MO et. al.

Dec 29th, 2020 - The main aim of this study is to compare the 2 medications denosumab and zoledronic acid for patients with beta-thalassemia major induced osteoporosis. Patients with B-thalassemia major induced osteoporosis will undergo baseline assessment of the ...

The spectrum of beta-thalassemia mutations in the 22 Arab countries: a systematic review.
https://doi.org/10.1080/17474086.2021.1860003
Expert Review of Hematology; Khan AM, Al-Sulaiti AM et. al.

Dec 15th, 2020 - To investigate the mutational spectrum in the HBB gene in Arab patients with β-thal. Authors searched five databases (PubMed, Science Direct, Scopus, Web of Science, and Google Scholar) from the time of inception until March 2020. The authors sear...

see more →

Guidelines  1 results

Cardiovascular Function and Treatment in Beta-Thalassemia Major
https://www.ahajournals.org/doi/abs/10.1161/CIR.0b013e31829b2be6?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed
Pennell, D.,et al.

Jun 30th, 2013 - This aim of this statement is to report an expert consensus on the diagnosis and treatment of cardiac dysfunction in ?-thalassemia major (TM). This consensus statement does not cover other hemoglobinopathies, including thalassemia intermedia and s.

see more →

Drugs  2 results see all →

Clinicaltrials.gov  1,207 results

New Gene Therapy Vector Promising for Sickle Cell, Beta-Thalassemia
https://www.medscape.com/viewarticle/945626

Feb 10th, 2021 - NEW YORK (Reuters Health) - A new lentiviral gene therapy vector, ALS20, triggers more hemoglobin production at a lower dose than vectors currently used in trials of blood disorders such as sickle cell disease and beta-thalassemia, researchers say...

A Rare Case of von Willebrand Disease Presenting as Hemolacria and Literature Review.
https://doi.org/10.1097/MPH.0000000000002077
Journal of Pediatric Hematology/oncology; Nandakumal G, Ismail F et. al.

Feb 9th, 2021 - Hemolacria is a rare condition that causes a person to produce tears that are partially composed of blood. It can be a presenting feature of certain ocular and systemic conditions. Here, the authors describe an interesting case of a 12-year-old bo...

Beta-Thalassemia - GeneReviews® - NCBI Bookshelf
https://www.ncbi.nlm.nih.gov/books/n/gene/b-thal/

Feb 3rd, 2021 - Beta-thalassemia (β-thalassemia) is characterized by reduced synthesis of the hemoglobin subunit beta (hemoglobin beta chain) that results in microcytic hypochromic anemia, an abnormal peripheral blood smear with nucleated red blood cells, and red...

The effect of curcumin on serum copper, zinc, and zinc/copper ratio in patients with β-...
https://doi.org/10.1007/s00277-021-04397-z
Annals of Hematology; Saeidnia M, Nowrouzi-Sohrabi P et. al.

Jan 12th, 2021 - Thalassemia intermedia is a subgroup of β-thalassemia which originates from mutations in the beta-globin gene. Zinc and copper play important roles in the metabolism. Due to its significant therapeutic effects, curcumin has led many studies to foc...

Denosumab versus zoledronic acid for patients with beta-thalassemia major-induced osteo...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7748343
Medicine Yassin MA, Abdel Rahman MO et. al.

Dec 29th, 2020 - The main aim of this study is to compare the 2 medications denosumab and zoledronic acid for patients with beta-thalassemia major induced osteoporosis. Patients with B-thalassemia major induced osteoporosis will undergo baseline assessment of the ...

see more →

News  31 results

New Gene Therapy Vector Promising for Sickle Cell, Beta-Thalassemia
https://www.medscape.com/viewarticle/945626

Feb 10th, 2021 - NEW YORK (Reuters Health) - A new lentiviral gene therapy vector, ALS20, triggers more hemoglobin production at a lower dose than vectors currently used in trials of blood disorders such as sickle cell disease and beta-thalassemia, researchers say...

Quercetin may reduce iron overload in beta-thalassemia major
https://www.mdedge.com/hematology-oncology/article/207259/bleeding-disorders/quercetin-may-reduce-iron-overload-beta?channel=39313
Caleb Rans

Aug 28th, 2019 - Combination quercetin and desferrioxamine could decrease iron overload in patients with transfusion-dependent beta-thalassemia major, according to a randomized clinical study. Over the course of treatment, quercetin was well tolerated and no major.

Novel conditioning regimen shows benefit for beta-thalassemia major
https://www.mdedge.com/hematology-oncology/article/207231/bleeding-disorders/novel-conditioning-regimen-shows-benefit-beta?channel=341
Caleb Rans

Aug 28th, 2019 - A novel transplant protocol (WZ-14-TM) improved survival outcomes and rates of graft-versus-host disease (GVHD) in patients with beta-thalassemia major undergoing hematopoietic stem cell transplant (HSCT) from an unrelated donor, according to find.

Luspatercept Reduces Blood Transfusions in MDS and Beta-Thalassemia
https://www.medscape.com/viewarticle/905867

Dec 1st, 2018 - SAN DIEGO — The investigational drug luspatercept (under development by Acceleron and Celgene) has been shown to reduce the need for blood transfusions in two separate patient populations. The product, a first-in-class erythroid maturation agent t...

Blood disorders researcher is finalist for Trailblazer Prize
https://www.mdedge.com/hematology-oncology/article/173229/bleeding-disorders/blood-disorders-researcher-finalist
Mary Ellen Schneider

Aug 22nd, 2018 - Daniel Bauer, MD, PhD, a pediatric hematologist and blood disorders researcher in Boston, is one of three finalists for the inaugural Trailblazer Prize for Clinician-Scientists, which is awarded by the Foundation for the National Institutes of Hea.

see more →